A Personal Mission to Reprogram the Human Immune Response to Cancer
Often when we discuss life sciences, particularly as investors, the human element gets lost. The focus tends to be on the pipeline, clinical and preclinical progress, data, efficacy, cash runway, and addressable market. These and other inputs can be plugged into a model to provide insight into a company’s chance of success. But this process…
ME Therapeutics Holdings Inc. (CSE:METX)





